

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/IL05/000093

International filing date: 26 January 2005 (26.01.2005)

Document type: Certified copy of priority document

Document details: Country/Office: IL
Number: 160095
Filing date: 28 January 2004 (28.01.2004)

Date of receipt at the International Bureau: 03 March 2005 (03.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse




מדינת ישראל
STATE OF ISRAEL

Ministry of Justice
Patent Office

משרד המשפטים
לשכת הפטנטים

This is to certify that
annexed hereto is a true
copy of the documents as
originally deposited with
the patent application
particulars of which are
specified on the first page
of the annex.

זאת לתעודה כי
רצופים בזה העתקים
נכונים של
שהופקדו לכתחילה
עם הבקשה לפטנט
לפי הפרטים הרשומים
בעמוד הראשון של
הנספח.



רשם הפטנטים

Commissioner of Patents

נתאשר
Certified

לשימוש הלשכה
For Office Use

מספר:
160095 Number

תאריך:
Date

28-01-2004 הוקדם/נדחה
Ante/Post-dated

חוק הפטנטים התשכ"ז 1967-
PATENTS LAW, 5727-1967

ב ק ש ה ל פ ט נ ת
Application for Patent

אני, (שם המבקש, מענו – ולגבי גוף מאוגד – מקום התאגדותו)
I (Name and address of applicant, and, in case of a body corporate, place of incorporation)

1. Yisum Research Development
Company of the Hebrew University
of Jerusalem
Hi Tech Park
Edmond Safra Campus
Givat Ram
Jerusalem 91390
ISRAEL

2. Bio-Dar, Ltd.
Yavne Technology Park,
Building 10
P.O.Box 344
Yavne 81103
ISRAEL

2. ביו-דאר, בע"מ
פארק טכנולוגי יבנה,
בנין 10
ת"ד 344
יבנה 81103

1. יישום חברה לפיתוח המחקר
של האוניברסיטה העברית בירושלים
פארק הייטק
קמפוס אדמונד ספרא
גבעת רם
ירושלים 91390

ששמה הוא:
Owner, by virtue of

בעל אמצאה מכח הדין
of an invention, the title of which is:

פורמולציות עבור תרופות קשות תמס

(בעברית)
(Hebrew)

FORMULATIONS FOR POORLY SOLUBLE DRUGS


(באנגלית)
(English)

Inventors: MAGDASSI Shlomo, COHEN Keren, SELA Yoram

הממציאים: מגדסי שלמה, כהן קרן, סלע יורם

hereby apply for a patent to be granted to me in respect thereof.

מבקש בזאת כי ינתן לי עליה פטנט.

* בקשת חלוקה - Application for Division	* בקשת פטנט מוסף Application for Patent of Addition	* דרישת דין קדימה Priority Claim		
* מבקשת פטנט from Application מס' _____ Dated _____ מיום	* לבקשה / לפטנט To Patent/Apl. מס' _____ Dated _____ מיום	מספר/סימן Number/Mark	תאריך Date	מדינת האיגוד Convention Country
* יפוי כח: כללי/מיוחד – רצוף בזה / עוד יוגש P.O.A.: general / specific - attached / to be filed later - הוגש בענין _____				
המען למסירת הודעות ומסמכים בישראל Address for Service in Israel ריינהולד כהן ושותפיו עורכי פטנטים רח' אחד העם 21 ת.ד. 4060 תל-אביב 61040				
חתימת המבקש Signature of Applicant 		היום 27 בחודש ינואר שנת 2004 This 27 of January 2004		
		לשימוש הלשכה For Office Use		

REFERENCE: סימוכין: 2012-1584-0

טופס זה, כשהוא מוטבע בחותם לשכת הפטנטים ומושלם במספר ובתאריך ההגשה, הינו אישור להגשת הבקשה שפרטיה רשומים לעיל.
This form, impressed with the Seal of the Patent Office and indicating the number and date of filing, certifies the filing of the application, the particulars of which are set out above.

* מחק את המיותר inapplicable Delete whatever is

FORMULATIONS FOR POORLY SOLUBLE DRUGS

פורמולציות עבור תרופות קשות תמס

FORMULATIONS FOR POORLY SOLUBLE DRUGS

FIELD OF THE INVENTION

The present invention generally concerns formulations for drugs, and more particularly formulations for poorly soluble drugs.

BACKGROUND OF THE INVENTION

5 Solubility is defined as the concentration of the solute in a saturated solution. The solubility of compounds varies in accordance with factors such as temperature, the type of solvent, the pH of the solution, and atmospheric pressure. The solubility of drugs found in the US Pharmacopeia is expressed as the number of milliliters of solvent in which one gram of solute can dissolve. Where the exact
10 solubility of various compounds cannot be precisely determined general quality terms are used to describe the solubility of a specific compound, typically with reference to other compounds. Solubility may also be expressed in terms of molarity, percentage, and molality. Typically, drugs defined as "*poorly soluble*" are those that require more than 1 ml part of solvent per 10 mg of solute. Some poorly
15 soluble drugs are further limited by their intrinsic bioavailability for example due to extensive first pass metabolism by the liverok (first pass effect), or further limited due to various drug-drug interactions .

Usage of poorly soluble compounds has increased by 25% on average over the last five year period. The increase in formulations containing poorly soluble
20 compounds is attributed to factors associated with both the pharmaceutical and biotechnology sectors. For example, within the pharmaceutical sector, drugs are now more frequently designed by combinatorial chemistry in order to improve their distribution through various tissues in the body, increase their half life, and improve

their therapeutic index (more potency with low concentrations). Sometimes newly developed drugs produced by combinatorial techniques are poorly soluble as during development, and in contrast to rational drug design, solubility was never a factor considered for their production.

5 In the biotechnology field, compounds, such as peptides, nucleic acid sequences, monoclonal antibodies, etc. resulting from biotechnological development are also typically poorly soluble.

There are several different approaches to solve the problem of solubility of poorly soluble drugs. These include traditional solubilizing approaches using a
10 combination of solvents, surfactants and co-solvents, various sophisticated dispersion systems, as well as novel technologies, including micronization, complexation and liposomal delivery.

One approach directed to delivery and release of poorly soluble drugs is their formulation as nano sized particles/crystals.

15 U.S. Patent Application 20030215513 concerns release of substantially water insoluble nano-sized particles from a composition, by coating the pharmaceutical composition with a diffusion-control membranes that contains a multiplicity of pores and pore-forming substances. This establishes a diffusion gradient that enables mass-transport of nano-suspensions from the pharmaceutical
20 composition through the pores, thereby resulting in a diffusion controlled release through the membrane.

U.S. Patent Application 20020106403 discloses a water insoluble drug, in a nanometer or micrometer particulate solid format, which is surface stabilized by a phospholipid, being dispersed throughout a bulking matrix. This construction can
25 dissolve upon contact with aqueous environments, thereby releasing the water insoluble particulate solid in an unaggregated or un-agglomerated form. Typically, the matrix is composed of water insoluble substance.

U.S. Patent No. 5,439,686 discloses compositions for *in vivo* delivery of water insoluble pharmaceutical agents, notably the anticancer drug taxol, wherein

the active agent is solubilized in a biocompatible dispersing agent contained within a protein walled shell. By another alternative, the protein walled shell can contain particles of the taxol itself.

U.S. Patent No. 6,387,409 discloses nano- or micro-sized particles of water
5 insoluble, or of poorly soluble drugs, produced by a combination of natural and synthetic phospholipids and charge surface modifiers such as highly purified charge phospholipids, together with a block copolymer which are coated or adhered on to the surfaces of water insoluble compound particles. These constructs enable the formation and stabilization of submicron and micron sized compound particles
10 stabilized by the charge phospholipids which provides electrostatic stabilization; and stabilized by the block copolymer to provide steric stabilization. Such constructs prevent the particles from aggregation and flocculation.

International Patent Application WO 9725028 concerns controlled release beads which comprise a core of insoluble drugs, and a layer of furosemide
15 dispersed in a hydrophilic polymer and a membrane which regulates the release of the furosemide in a controlled manner.

U.S. Patent No. 6,645,528 concerns poorly soluble drugs provided in a porous matrix form which enhances the dissolution of the drug in an aqueous media. The pore forming agent creating the porous matrix is typically a volatile
20 liquid that is immiscible with the drug solvent, or alternatively, a volatile solid compound such as a volatile salt. The resulting porous matrix has a faster rate of dissolution following administration to a patient as compared to a non porous matrix form of the drug.

Sustained, or controlled release drug delivery systems, include any drug
25 delivery system that achieves a slow release of a drug over an extended period of time. The main aim of slow release systems is improved efficiency of treatment as a result of obtaining constant drug-blood levels, thus maintaining the desired therapeutic effect for extended periods of time. This results in reduction and

elimination of fluctuations in blood levels, thus allowing better disease management.

Some controlled release systems were not developed for the main purpose of sustained release, by rather having been developed in order to improve the bioavailability of drugs, due to their activity in isolating the drugs from the environment, for example by protecting drugs susceptible to enzymatic inactivation or bacterial decomposition by encapsulation in polymeric systems.

Microparticles containing poorly soluble drugs and a polymer were prepared in order to overcome some technical problems of tabulating encountered during formulations of medicaments with microparticles. In these formulations propranolol was the poorly soluble drug, and the polymer was ethylcellulose. Together, the polymer and the poorly soluble drugs were mixed to form microspheres containing a drug-polymer mixture, which were subsequently entrapped within a chitosan or calcium alginate beads. Thus the beads contained initially a mixture of drugs and insoluble polymers, subsequently mixed with a soluble polymer. The ionic characteristics of the polysaccharides of this delivery system allowed a pH-dependent release of the microparticles in the gastrointestinal tract (Bodmeier *et al.* Pharmaceutical Research 6:5, 1989).

SUMMARY OF THE INVENTION

The present invention is based on the realization that particles of poorly soluble drugs can have improved solubility, and hence improved bioavailability, if they are administered dispersed in a hydrophilic polymeric bead in the form of nanoparticles of the drug.

Thus, by one aspect the present invention concerns a drug delivery system comprising nanoparticles or microparticles dispersed in a polymeric bead containing essentially of only hydrophilic polymers (i.e. without hydrophobic polymers).

By a preferred embodiment, the drug delivery system of the invention the polymeric beads consisting essentially of a single hydrophilic polymer, this being in a contrast to the publication of Bodmeier *et al.* wherein the poorly soluble drug is first entrapped within an insoluble polymer, and the microparticles of the insoluble
5 polymer and drug are then mixed with a soluble-polymer forming bead. Therefore, by Bodmeir publication one obtains drug molecules entrapped within a water insoluble polymeric matrix, which leads to decreased solubility of the drug, and that would cause a decreased bioavailability.

Against this, the beads of the present invention consists of drug
10 nanoparticles essentially free of water insoluble polymer, while the single hydrophilic polymer serves as a former of porous bead, which prevents the increase in the size of the drug particle, and greatly simplifies the manner of production as will be explained hereinbelow.

In addition, in accordance with one preferred embodiment of the invention,
15 the bead formation process by itself leads to formation of the drug nanoparticles, which are formed from a nanoemulsion, in a way that overcomes the problems associated with conventional methods for preparation of nanoparticles by solvent evaporation from submicron emulsions. The beads themselves serve as the delivery system, having the ability of controlling the release of the nano/micro particles of
20 the poorly soluble drugs there from. The control can be achieved by the inherent polymeric structure of the bead, or by a combination of the bead skeleton polymers and polymeric additives, mainly water soluble polymers.

The term "*drug delivery system*" in the context of the present invention concerns active ingredient - i.e. the drug - in its carrier matrix. The drug delivery
25 system in accordance with the invention may be used for subsequent preparation of dosage administration forms, for example, in the form of capsules (coated or uncoated), tablets (coated or uncoated), wherein the coating may be functional such as enteric coating, colonic delivery coating, chrono-therapeutic and controlled release coating, taste-masking coating and the like. The dosage form may be

suitable for any mode of administration such as oral, rectal, depo-administration, parenteral, subcutaneous, ocular, nasal, vaginal and the like.

The term "*polymer*" in accordance with the present invention shall be understood as referred both to a polymer composed of a single re-occurring
5 building block (monomer) as well as to a polymer composed of two or more different polymeric units (co-polymer).

The term "*poorly soluble drug*" refers to a drug which is poorly soluble in an aqueous solution, and typically this refers to a drug which has a solubility of less than 10 mg/ml, and preferably less than about 5 mg/ml in aqueous media at
10 approximately physiological temperature and pH. As used herein, the term "*drug*" refers to chemical and biological molecules having therapeutic, diagnostic or prophylactic effects *in vivo*.

Drugs contemplated for use in the system described herein include the following categories and examples of drugs and alternative forms of these drugs
15 such as alternative salt forms, free acid forms, free base forms, and hydrates: Accupril (Quinapril), Accutane (Isotretinoin), Actos (Pioglitazone), AeroBid (Flunisolide), Agenerase (Amprenavir), Akinetron (Biperiden), Allegra (Fexofenadine), Aromasin (Exemestane), Asacol (Mesalamine), Atacand (Candesartan cilexetil), Avandia (Rosiglitazone), Azmacort (Triamcinolone), Biaxin
20 (Clarithromycin), Camptosar (Irinotecan), Cefzon (Cfdinir), Celebrex (Celecoxib), Claritin (Loratadine), Clinoril (Sulindac), Cordarone (Amiodarone HCL), Diovan (Valsartan), Duragesic (Fentanyl citrate), DynaCirc (Isradapine), Elmiron (Pentosan polysulfate sodium), Elconon/Nasonex (Mometasone), Epogen/Procrit (EPO), Estratest (Methyltestosterone), Evista (Raloxifene hydrochloride), Fareston
25 (Toremifene citrate), Flomax (Tamsulosin hydrochloride), Follistim (Follitropin beta), Halcion (Triazolam), Hismanal (Astemizole), Hydergine LC (Ergoloid mesylates), Imodium (Loperamide), Invirase (Saquinavir), Lipitor (Atorvastatin Calcium), Luvox (Fluvoxamine), Mevacor (Lovastatin), Neoral and Sandimmune (Cyclosporine), Nitorol-R/Frandol (Isosorbide dinitrate), Noroxin (Norfloxacin),

Norvir (Ritonavir), Pepcid (Famotidine), Platinol-AQ (Cisplatin), Plavix (Clopidrogel bisulfate), Plendil (Felodipine), Pletal (Cilostazol), Pulmicort Turbuhaler/Rhinocort (Budesonide).

The drugs may also include biological produced agents such as proteins, protein fragments, peptides, nucleic acid sequences, oligonucleotides, glycoproteins as long as they are water insoluble

Most preferable drugs are simvastatine, statines, risperidone, carvedilol, carbamazepine, oxcarbazepine, zaleplon, galantamine, avandia, and poorly soluble anti psychotic, anti epileptic, anti parkinsonian and other indicated for CNS indications.

The polymeric bead is composed of either a polysaccharide polymer, a protein or a synthetic polymer, which may be either crosslinked, or not crosslinked

Examples of polysaccharide polymers are: alginates, chitosans, gellan gums, agarose, pectin, carrageenan.

Examples of proteins are: gelatins, albumins, lactalbumin.

Examples of synthetic polymers are polyacrylic acid. The term "nanoparticles" refer to poorly soluble drugs which have the size of 3 nm to 900 nm, preferably 5 nm to 450 nm.

The term "microparticles" refer to poorly soluble drugs which have the size of 1 to 500 micrometers .

Preferably, in accordance with the present invention, the nanoparticles or microparticles are in an amorphous state, which increases their solubility rate, and subsequent crystallization is prevented due to the presence of hydrophilic polymer and surfactants used in the process of production.

Still more preferably, in accordance with the invention, the drug delivery system may include externally added crosslinking agents, which are, for anionic polyssacharides and synthetic polymers, multivalent cations, such as calcium, magnesium, barium, ferrous, polycations and cupper salts. For cationic polymers, such as chitosan, a polyvalent anion such as tripolyphosphate or anionic polymers

may be used. It should be noted that the polymeric beads may be also formed by heating-cooling effects, such as formation of gelatin beads, which is obtained by dropwise addition of warm gelation solution into cold liquid, water or oil.

Still more preferably, the drug delivery system including said externally added crosslinking agents, further comprises a disintegrant which may be a chelator of the crosslinking cation, for example calcium or magnesium. Such chelators, in contact with water, interact with the crosslinking agents, thus breaking the crosslinking of the polymeric bead and enhancing the disintegration of the bead.

Examples of such chelators are EDTA, sodium citrate, citric acid, sodium dodecyl sulfate, phosphate salts and phosphate buffer saline. By using a disintegrant mixed with the polymer bead in the delivery system of the invention, it is possible on the one hand to improve the solubility of the poorly soluble drugs by using the drug in the form of nanoparticles, and on the other hand to obtain rapid disintegration of the bead, for example in the gastrointestinal tract, in such a way that the drug nanoparticles are in close contact with the dissolution medium, without any barrier that could be formed by the crosslinked polymer.

Such a construct which is unusual for polymeric beads, which typically are constructed without a disintegrant for sustained-release purposes, which results in drug particles that remain entrapped in the beads' core leading to slower dissolution rate and consequently to reduced bioavailability.

Thus the present invention concerns a drug delivery system comprising an active ingredient dispersed within a polymeric bead, wherein the polymer may be crosslinked, while the crosslinking is achieved (in case of sodium alginate, for example) by a multivalent cation such as calcium, magnesium, barium, ferrous or copper salts and wherein the drug delivery system further comprises as a disintegrant, a chelator of the multivalent cation.

Preferably, the drug is a poorly soluble drug, more preferably in the form of a nano-particle, a micro-particle, most preferably in the form of a nanoparticle.

The present invention further concerns a method of producing the drug delivery system of the invention comprising:

- 5 (i) dissolving poorly water soluble drugs in organic volatile solvent, optionally in the presence of at least one surfactant;
- (ii) mixing the drug-containing solvent with an aqueous phase, optionally in the presence of at least one surfactant, cosolvents and electrolytes thereby producing an oil-in-water nano- or micro emulsion;
- 10 (iii) mixing the oil-in-water emulsion with water-soluble bead-forming polymers to produce a continuous phase of the emulsion which contain the bead forming polymer;
- (iv) providing conditions enabling bead formation from the continuous phase of (ii) containing nanoemulsion or
15 microemulsion in the matrix of the bead;
- (v) drying of the beads, by evaporating the volatile organic solvent and the aqueous phase of the bead;

thereby obtaining dry beads containing in their matrix dispersed
20 nanoparticles or microparticles of poorly water-soluble drugs, optionally in presence of surfactants .

The beads containing the drug nanoparticles or microparticles obtained by the method of the invention may be formulated to form a suitable dosage form, for example they may be packed within a capsule or a tablet, optionally together with a
25 disintegrant as will be explained herein bellow, , thus providing a delivery system of the poorly soluble drug. Alternatively polymeric additives may be added in order to control the drug release.

The poorly soluble drug is rendered in a nanoparticle form by consequent evaporation of the organic solvent and the water, thus the previously dissolved drug

in the solvent droplets, becomes insoluble, and having a size similar to the initial size of the nanoemulsion droplets, and in most cases having a non-crystalline morphology. Since each nanoemulsion droplet is dispersed within the crosslinked polymeric network of the bead, there is no possibility for coalescence of emulsion droplets, and therefore there is no increase in the size of drug particles which are maintained in their original nanoparticle size. In addition, since the evaporation of the solvent is rapid, and performed within a viscous, crosslinked polymeric network (which becomes more viscous as evaporation proceeds), the obtained drug nanoparticles are amorphous (not crystalline).

Furthermore, due to the presence of the surfactants in the nanoemulsion the nanoparticles remain in an amorphous structure that brings significant advantages for enhanced dissolution and bioavailability.

As will be shown in the examples, the processes described in this invention allow obtaining nanoparticles of drugs, which otherwise, upon application of conventional solvent evaporation method, would have formed large crystals. It was surprisingly found that by performing the solvent evaporation process only after the beads are formed, the crystallization and increase of the size of the drug molecule could be prevented.

Non-limiting of suitable organic volatile solvents are: toluene, butyl acetate, ethyl acetate, methylene chloride, chloroform and limonene.

Examples of suitable surfactants are: nonionic surfactants such as: block copolymers such as Pluronic F 68, Polyglycerol esters, alkyl glucosides ethoxylated sorbitan esters and ethoxylated sorbitan esters, ionic surfactants such as lecithin, sodium dodecyl sulphate, and polymers such as polyvinyl alcohol, gelatin and BSA.

The surfactants are selected from molecules acceptable for pharmaceutical preparations, which are capable of yielding nanoemulsions or microemulsions. The nanoemulsions can be formed by various methods, preferably by using a high pressure homogenization technology.

This emulsion is subsequently mixed with a water-soluble polymer capable of forming polymeric beads to produce a continuous phase.

Examples of such polymers are sodium alginate, sodium polyacrylate, chitosan and gelatin.

5 Beads are formed by solidifying drops of solutions containing the bead forming polymers either by contact with a crosslinking agent (when the polymer can react with the crosslinking agent to form an insoluble polymeric structure), or by solidification, for examples while using a polymer such as gelatin, which forms a liquid solution at elevated temperature, and solidifies at room temperature.

10 Thus, while the bead forming solution is added as small droplets through a suitable orifice, into a crosslinking solution or simply in a cold environment in case of temperature induced bead formation, immediate crosslinking (similar to solidification) of the external part of the bead occurs, and therefore the external part of the droplets becomes solid.

15 Upon further exposure to the crosslinking solution, the crosslinking ions migrate into the interior part of the bead, and form a solid matrix throughout the whole bead.

The structure of the beads (porosity, rigidity etc.) can be tailored by proper selection of the bead formation conditions (such as crosslinker concentration, 20 duration of crosslinking , presence of various electrolytes etc.). The size of the beads can be controlled by proper selection of the nozzle diameter and instrumentation from which the bead forming polymeric solution is ejected.

Finally, as a last stage, the volatile (organic solvent) is evaporated together with the aqueous phase, for example by application of vacuum or by lyophilization 25 processes, or by simply drying at room temperature, to obtain the dry beads containing in their matrix dispersed nanoparticles of the poorly soluble drug.

At the last preparation step, the beads are packed in a suitable pharmaceutical formulation such as gelatin capsule or solid tablet (containing conventional pharmaceutical excipients), and optionally containing agents which

enhance the disintegration of the beads upon contact with body fluids. Such disintegrators can be molecules capable of replacing the crosslinking agent, such as chelators of the crosslinking agents such as EDTA, citric acid, sodium citrate, sodium dodecyl sulfate, phosphate salts or phosphate buffer saline.

5 Thus, when the polymeric beads are placed in an aqueous solution (such as in the gastrointestinal tract) water activates the chelating agent, causing it to chelate the crosslinkers (such as calcium ions), thereby disintegrating the beads and speeding up the release of the drug therefrom. Agents which modify the release, such as polymers may be added to the pharmaceutical dosage forms as well for
10 decreasing rather than increasing, the release rate.

Polymeric bead properties can be tailored to meet various requirements for proper drug dissolution as will be explained below.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in
15 practice, some preferred embodiments will now be described, by way of non-limiting examples only, with reference to the accompanying drawings, in which:

Fig. 1A shows an electron microscope picture of a polymeric bead containing nanoparticles of simvastatine, prepared as described in Example 1 which are vacuum dried;

20 **Fig 1B** shows an electron microscope picture of a polymeric bead containing nanoparticles of simvastatine, prepared as described in Example 1 which are air dried.

Fig. 2 shows the dissolution of two samples of beads of the invention containing simvastatine as compared to dissolution of commercial simvastatine.

25 **Fig. 3** shows an electron microscope picture of simvastatine crystals after solvent evaporation carried out without using bead formation.

Fig. 4 shows electron microscope pictures of simvastatine nanoparticles after solvent evaporation from bead nanoemulsion systems.

Fig. 5 shows the effect of varying concentrations of phosphate buffer (pH ~ 6.8) on beads disintegration.

Fig. 6 shows the effect of varying concentrations of citrate buffer (pH ~ 6.8) on beads disintegration.

5 Fig. 7 shows the effect of various crosslinking ions at a concentration of 25 mM on beads disintegration.

Fig. 8 shows the effect of various crosslinking ions at a concentration of 100 mM on beads disintegration.

10

DETAILED DESCRIPTION OF THE INVENTION

Tailoring of the polymeric bead parameters:

Examples of drug nanoparticles and bead parameters that can be tailored by varying the following parameters:

- 15 1) Droplets size in the nano/microemulsion may be tailored by controlling volatile solvent type, surfactants and cosurfactant concentration and type, by controlling the cycles in high-pressure homogenizer, o/w ratio.
- 20 2) Type and molecular weight of the polysaccharide, (Alginate, K-Carrageenan, Chitosan, Gellan gum, Agarose, Pectin etc,) or synthetic polymers.
- 3) Structure of alginates (different ratio of guluronic and mannuronic acids).
- 25 4) Type and concentration of the crosslinking agent (also termed “gelling agent”) ion solution (cation: Ca^{+2} , Ba^{+2} , AL^{+3} , Fe^{+2} , Cu^{+2} , poly(amino acids) etc., and non-crosslinking ion (and Na^{+}).

- 5) Crosslinking duration.
- 6) Matrix composition of material other than the bead forming polymer, other materials may be added, such as Silica, HPMC, Lactose etc., which affect the morphology, porosity, size, and shrinkage of beads upon drying, disintegration rate and hydrophobicity.
- 7) The size of the polysaccharide beads can be controlled by controlling nozzle size, frequency, amplitude, velocity, physical parameters.
- 8) The rate of disintegration may be controlled by adding a disintegrant such as EDTA, phosphate or citrate ions, and controlling the amount of the disintegrant.

EXAMPLE 1:

Solutions preparations:

4% Alginate solution:

16g of Alginic acid sodium salt (Sigma, low viscosity, 2% solution-250cps) was dissolved in 400g distilled water (4% w/w), together with 0.4g of Bronopol (preserving material). The mixture was mixed on magnetic stirrer for about 48 hours and heated to about 37°C until complete dissolution.

100mM CaCl₂ solution (crosslinking agent)

14.8g of Dihydrate Calcium Chloride (Merck) was dissolved in 1000g distilled water.

1. Emulsification

Oil in water emulsion 20% oil phase fraction , 80% aqueous phase fraction was prepared, 3% w/w total surfactant (Tween 20-ethoxylated sorbitan monolaurate, Span 20-sorbitan monolaurate HLB=10) concentration.

3.3584g of Simvastatine powder (Teva Pharmaceuticals, Israel) used as the poorly soluble drug was weighed and mixed with 80.0g toluene until complete dissolution of the drug is achieved. Final concentration of Simvastatine is 42mg/g Simvastatine .

5 1.02g Tween 20 was weighed and dissolved in 160.26g distilled water saturated with toluene (filtered through 0.2 μ m filter) .

4.97g span 20 was weighed and mixed with the 40.23g solution of 42mg/g Simvastatine in toluene, and stirred about 10min together. The organic phase was added carefully to the water phase and mixed for 5 min in an Ultra Turrax
10 homogenizer at 8000 RPM. A coarse, homogeneous emulsion was obtained. This emulsion was introduced into a high pressure homogenizer (Stansted), and was circulated through the high-pressure-homogenizer twice at 17,000 psi.

Z-average particles size of the resulting emulsion was 250-255nm.

15 2. **Beads formation:**

95.1g of sodium alginate solution (4% w/w) and 3.8g of Silica 60 \AA Frutarom) used to prevent shrinking upon drying, were mixed together for about 10 min by a magnetic stirrer until the silica was dispersed homogeneously in the alginate solution. Then 95.1g of the above o/w emulsion were added and stirred
20 together until homogenous mixture was achieved. The alginate- emulsion mixture was introduced into an Innotech encapsulator, and jetted into 100mM CaCl₂ crosslinking solution.

The Innotech encapsulator allows tailoring the final size of the beads by selecting the proper instrument parameters. In this example, the parameters were:

25 Nozzle size – 300 μ m.

Voltage – 0.914 Kv.

Amplitude – 3.

Frequency –1550 Hz.

Pressure ~0.4 bar.

The beads were kept in the crosslinking solution for 30min.

Then, the beads were rinsed with about 2 liters of distilled water, filtered and air dried in an oven, at temperature of about 35°C for 48 hours, in order to remove the water and the volatile solvent.

5 The final result was dry beads in the size range of less than 1 mm in which nanoparticles of Simvastatine were dispersed, as verified by electron microscopy as shown in Fig. 1.

EXAMPLE 2: Reduction of gelling time and gelling ion concentration.

Solutions preparations:

4% Alginate solution:

Was carried out as described in Example 1.

25mM CaCl₂ solution (crosslinking agent)

3.7g of Dihydrate Calcium Chloride (Merck) was dissolved in 1000g distilled water.

10 **1. Emulsification**

Oil in water emulsion 20% oil phase fraction, 80% aqueous phase fraction was prepared, 3% w/w total surfactant (Tween 20-ethoxylated sorbitan monolaurate, Span 20-sorbitan monolaurate HLB=10) concentration 3.7869g of Simvastatine powder (**Teva Pharmaceuticals, Israel**) used as the poorly soluble
15 drug was weighed and mixed with 90.1g toluene until complete dissolution of the drug is achieved. Final concentration of Simvastatine is 42 mg/g Simvastatine .

1.04g Tween 20 was weighed and dissolved in 160.54g distilled water saturated with toluene (filtered through 0.2 µm filter) .

4.97g span 20 was weighed and mixed with the 40.55g solution of 42mg/g
20 Simvastatine in toluene, and stirred about 10min together. The organic phase was added carefully to the water phase and mixed for 5 min in an Ultra Turrax homogenizer at 8000 RPM. A coarse, homogeneous emulsion was obtained. This emulsion was introduced into a high pressure homogenizer (Stansted), and was circulated through the high-pressure-homogenizer twice at 17,000 psi.

25 Z-average particles size of the resulting emulsion was 194 -210nm.

2. **Beads formation:**

75.3g of sodium alginate solution (4%w/w) and 3.0g of Silica 60Å (Frutarom) were mixed together for about 10 min by a magnetic stirrer until the silica was dispersed homogeneously in the alginate solution. Then 75.2g of the
5 above o/w emulsion were added and stirred together until homogenous mixture was achieved. The alginate- emulsion mixture was introduced into an Innotech encapsulator, and jetted into 25mM CaCl₂ crosslinking solution .

The Innotech encapsulator allows tailoring the final size of the beads by selecting the proper instrument parameters. In this example, the parameters were:

10 Nozzle size – 300µm.

Voltage – 1.005 Kv.

Amplitude – 3.

Frequency –1527 Hz.

Pressure ~0.3 bar.

15 The beads were kept in the crosslinking solution for 10min. .

Then, the beads were rinsed with about 2 liters of distilled water, filtered and air dried in an oven, at temperature of about 35°C for 48 hours, in order to remove the water and the volatile solvent.

20 **EXAMPLE 3: Alteration of surfactant**

Solutions preparations:

4% Alginate solution:

Was carried out as described in Example 1.

25 **25mM CaCl₂ solution (crosslinking agent) –**

Was carried out as described in Example 2.

1. Emulsification

Oil in water emulsion 20% oil phase fraction , 80% aqueous phase fraction was prepared, 3% (w/w) total surfactant (Hexaglycerol sesquistearate, SY-GLYSTER SS-5S, SAKAMOTO YAKUHHIN KOGYO CO., LTD. HLB=9.9) concentration 3.7807g of Simvastatine powder)(Teva Pharmaceuticals, Israel) used as the poorly soluble drug was weighed and mixed with 90.1g toluene until complete dissolution of the drug is achieved. Final concentration of Simvastatine is 42mg/g Simvastatine .

4.02g Hexaglycerol sesquistearate was weighed and dissolved in 160.28g distilled water saturated with toluene (filtered through 0.2 μ m filter) .

2.02g Hexaglycerol sesquistearate was weighed and mixed with the 40.46g solution of 42mg/g Simvastatine in toluene, and stirred about 10min together. The organic phase was added carefully to the water phase and mixed for 5 min in an Ultra Turrax homogenizer at 8000 RPM. A coarse, homogeneous emulsion was obtained. This emulsion was introduced into a high-pressure homogenizer (Stansted), and was circulated through the high-pressure-homogenizer twice at 17,000 psi.

Z-average particles size of the resulting emulsion was 126-140nm.

2. Beads formation:

75.2g of sodium alginate solution (4%w/w) and 3.0g of Silica 60Å(Frutarom) were mixed together for about 10 min by a magnetic stirrer until the silica was dispersed homogeneously in the alginate solution. Then 75.5g of the above o/w emulsion were added and stirred together until homogenous mixture was achieved. The alginate- emulsion mixture was introduced into an Innotech encapsulator , and jetted into 25mM CaCl₂ crosslinking solution .

The Innotech encapsulator allows tailoring the final size of the beads by selecting the proper instrument parameters. In this example, the parameters were:

Nozzle size – 300 μ m.

Voltage – 1.005 Kv.

Amplitude – 3.

Frequency – 1527 Hz.

5 Pressure ~0.3 bar.

The beads were kept in the crosslinking solution for 10min.

Then, the beads were rinsed with about 2 liters of distilled water, filtered and air dried in an oven, at temperature of about 35°C for 48 hours, in order to remove the water and the volatile solvent.

10

Dissolution tests

Dissolution test was performed to the dried beads and the results are shown in Fig. 2, where samples 2 and 3 are the beads of the invention compared to commercial simvastatine. [Please use in the graph provided a different color for
15 **simvastatine as yellow does not print in black and white printer**].

Dissolution test parameters:

Instrument: Caleva 7ST , Test method: USP II at 75rpm

Dissolution medium: Citarate Buffer 0.1M pH~6.8

Assay Procedure: UV at 239nm.

20 Dissolution test shows (see Fig. 2) the advantage of the beads of the invention, which uses hydrophilic polymer beads containing dispersed nanoparticles of simvastatine (water insoluble drug) by solvent evaporation upon commercial simvastatine particles.

The overall dissolution rate of the beads containing dispersed nanoparticles
25 is much faster than that of commercial drug particles. Using beads nanoparticles system enable tailoring of release kinetics.

The dried resulting beads can be inserted to capsules or compressed to tablets.

Example 4: Solvent evaporation of nanoemulsion in conventional way

In this example solvent evaporation was performed to the nanoemulsion before beads formation. This experiment prove the necessity of solvent evaporation after the beads formation in order to prevent crystal formation and
5 growing of the lipophilic drug.

1. Emulsification

Oil in water emulsion 20% oil phase fraction, 80% aqueous phase fraction was prepared, 3% (w/w) total surfactant (Tween 20-ethoxylated sorbitan monolaurate, Span 20-sorbitan monolaurate HLB=10) concentration 2.5231g of
10 Simvastatine powder(Teva Pharmaceuticals, Israel) used as the poorly soluble drug was weighed and mixed with 61.7g toluene until complete dissolution of the drug is achieved. Final concentration of Simvastatine is 41mg/g Simvastatine .

0.51g Tween 20 was weighed and dissolved in 80.26g distilled water saturated with toluene (filtered through 0.2 μ m filter).

15 2.49g span 20 was weighed and mixed with the 20.56g solution of 41mg/g Simvastatine in toluene, and stirred about 10min together. The organic phase was added carefully to the water phase and mixed for 5 min in an Ultra Turrax homogenizer at 8000 RPM. A coarse, homogeneous emulsion was obtained. This emulsion was introduced into a high pressure homogenizer (Stansted), and was
20 circulated through the high-pressure-homogenizer twice at 17,000 psi.

Z-average particles size of the resulting emulsion was 186-198nm.

The organic solvent (toluene) was evaporated with Rotavapor (R-114 BUCHI) from the emulsion to form a dispersion of lipophilic drug in water. The organic solvent evaporation was performed in four steps, water was added up to the
25 initial weight after each step.

After several hours, it was found that huge large crystals (needles) (crystal size: 0.5-2mm) of the raw material were formed (see Fig. 3) that indicate the instability of the drug nanoparticles that was formed after evaporation, while the evaporation is performed not within the polymeric bead..

Against this the solvent evaporation was performed after the beads formation the simvastatine remain as nanoparticles while performing the evaporation without beads forms large crystals of simvastatine (see Fig. 4). These experiments prove the necessity of solvent evaporation after the beads formation in
5 order to prevent forming and growing of the drug crystals, which significantly reduce the bioavailability of the poorly soluble drug.

EXAMPLE 5: Disintegrant effect on the beads

Alginate beads are insoluble in water or acidic media. In order to enable the
10 disintegration of the drug uptake, a disintegrant was included in the drug formulation, which contains the beads. The effect of disintegrant is demonstrated by experiments in which the beads were immersed in liquid containing the disintegrant.

The beads disintegration measurements were performed using turbidimeter
15 (HACH RATIO/XR). The turbidity values represent the beads disintegration. It is expected that the disintegration will enhance the drug release in the system. It should be emphasize that the beads cannot disintegrate without the presence of suitable disintegrating agents.

Fig. 5 demonstrates the influence of phosphate buffer concentrations, in the
20 range of 0.05M-0.25M, on the beads disintegration rate. In 0.05M phosphate buffer the beads were slightly disintegrated while in 0.25M phosphate buffer the beads were completely disintegrated within 10 mins.

Fig. 6 demonstrates the influence of citrate buffer concentrations, in the
range of 0.05M-0.25M, on the beads disintegration rate. The beads were
25 completely disintegrated within 10mins in all tested concentrations (0.05M-0.25M) of citrate buffer. The citrate buffer is more efficient disintegrating agent than phosphate buffer and it disintegrate the beads in lower concentration.

In addition to the examination of disintegrating agents (which is in the external phase) on the beads disintegration, the influence of various crosslinking

ions (Ca^{+2} , Ba^{+2} , Fe^{+3} , Zn^{+2} and Co^{+2}) in two different concentrations (which are added in the bead formation process) on the beads disintegration was determined.

Figs. 7 and 8 demonstrate the influence of different crosslinking cation on the beads disintegration.

5 It was found that the beads disintegration depends on the crosslinking ion according to the following order: $\text{Ca}^{+2} > \text{Zn}^{+2} > \text{Fe}^{+3} > \text{Co}^{+2} > \text{Ba}^{+2}$. The obtained order is influenced by several parameters such as: the cation valence, the cationic radius, and the ability of the disintegrating agent to competitive on the cation against the alginate polymer.

10 It was found that by proper selection of disintegrants (type and concentration) and crosslinking (type and concentration) we can control the release rate of the drug.

CLAIMS:

1. A drug delivery system comprising nanoparticles or microparticles of a poorly soluble drug dispersed in a polymeric hydrophilic bead.
2. A drug according to Claim 1, wherein the polymeric bead consists
5 essentially of a single species of polymer.
3. A drug delivery system according to Claim 2, wherein the polymeric bead is selected from: a polysaccharide polymer, a synthetic polymer, and a protein.
4. A drug delivery system according to Claim 3, wherein the polysaccharides are selected from: alginates, chitosans, gellan gum, agarose, pectin, carrageenan.
- 10 5. A drug delivery system according to Claim 3, wherein the synthetic polymer is : polyacrylic acid sodium salt
6. A drug delivery system according to Claim 3, wherein the protein is selected from gelatins, albumins, lactalbumins.
7. A drug delivery system according to any one of the preceding claims,
15 wherein the poorly soluble drug is selected from: simvastatine, statines, risperidone, carvedilol, carbamazepine, oxcarbazepine, zaleplon, galantamine, anti Alzheimer, anti epileptic, anti parkinsonian, and other used for CNS indications .
8. A drug delivery system according to Claim 1, wherein the nanoparticles are in an amorphous state, non crystalline state which enhances dissolution of the
20 drug..
9. A drug delivery system according to Claim 1, further comprising a crosslinker.
10. A drug delivery system according to Claim 9, wherein the crosslinker is a multivalent cation.
- 25 11. A drug delivery system according to claim 10, wherein the multivalent cation is selected from: calcium, barium, ferrous, magnesium or copper
12. A drug delivery system according to Claim 1, further comprising a disintegrate mixed with the beads.

13. A drug delivery system according to Claim 11 and 12, wherein the disintegrate is capable of breaking the crosslinking by replacing or chelation of the crosslinking multivalent cation.
14. A drug delivery system according to Claim 11 and 13, wherein the
5 disintegrate is a calcium chelator.
15. A drug delivery system according to Claim 14, wherein the calcium chelator is selected from EDTA, sodium citrate and citric acid.
16. A drug delivery system according to Claim 14, wherein the disintegrant is selected from sodium dodecyl sulfate, and phosphate buffer saline.
- 10 17. A drug delivery system according to claim 1 wherein the beads are formed without a cross linker.
18. A drug delivery system according to claim wherein the beads are gelatin beads forms by heating/cooling
19. A drug delivery system according to any one of the preceding claims in a
15 dosage form selected from: coated capsules, non-coated capsules, hard gelatin capsules, coated and non-coated tablets, suppositories, liquid suspensions for oral or parenteral administration, formulations for topical applications.
20. A drug delivery system according to Claim 19 in the form of coated hard gelatin capsules or coated tablets wherein the coating is selected from
20 entericoating, coating for colonic delivery and taste masking coating.
21. A drug delivery system comprising an active ingredient dispersed within a crosslinked polymeric bead wherein the crosslinking is by a calcium ion, barium, ferrous, magnesium or copper ions and wherein the drug delivery system further comprises as a disintegrant a chelator of calcium.
- 25 22. A drug delivery system according to Claim 21, wherein the active ingredient is a poorly soluble drug.
23. A drug delivery system according to Claim 20, wherein the poorly soluble drug is in the form of nanoparticles.
24. A method for producing the drug delivery system of Claim 1, comprising:

- (i) dissolving a poorly water soluble drug in an organic volatile solvent;
 - (ii) mixing the drug containing solvent with an aqueous phase containing at least one surfactant and optionally cosolvent and other emulsification aids at such conditions in which an oil-in-water nanoemulsion or microemulsion is formed;
 - (iii) mixing the oil-in-water nanoemulsion or microemulsion with water-soluble bead forming polymers to produce a continuous phase of the emulsion which is capable of forming a bead;
 - (iv) providing conditions enabling bead formation from the continuous phase of (iii) containing nano- microemulsion droplets;
- 15 evaporating the volatile organic solvent and the water thereby obtaining dry beads containing in the polymeric bead dispersed nanoparticles of poorly water soluble drugs.
25. A method according to Claim 24, wherein the mixing of the poorly water soluble drug in an organic solvent occurs in the presence of at least one surfactant.
- 20 26. A method according to Claim 24, wherein the drug containing solvent is mixed within an aqueous phase containing a surfactant the aqueous phase further containing a co-surfactant and/or co-solvent, and/or electrolytes.
27. A method according to Claim 24, wherein the volatile organic solvent is selected from: toluene, butyl acetate, ethyl acetate, methylene chloride, chloroform and limonene.
- 25 28. A method according to Claim 24, wherein the evaporation is carried out by application by air, vacuum by a lyophilizing process, or by drying under normal room conditions.

29. A method according to Claim 24, wherein the nanoemulsion is prepared by homogenization by a high pressure homogenizer or by a phase inversion method.
30. A method according to Claim 24, wherein the microemulsion is formed spontaneously by proper selection of the surfactants, solvent, co-solvent and co-
5 surfactants.
31. A method according to Claim 24, wherein at step (iv) the beads are incubated under suitable conditions and for suitable periods of time, with external crosslinking agents.
32. A method according to Claim 31, wherein the polymer is an anionic polymer
10 and external crosslinkers are multivalent cations selected from calcium, magnesium, copper, iron, barium salts and cations.
33. A method according to Claim 31, wherein the polymer is a cation polymer and external crosslinkers are polyvalent anions selected from polyanions or sodium tripolyphosphate.
- 15 34. A method for producing a pharmaceutical composition comprising packing the beads obtained in step (v) of Claim 24 within a capsule or tablet.
35. A method according to Claim 34, wherein disintegrator is added to the dry beads prior to packing the beads in a capsule or tablet.
36. A method according to Claim 35, wherein the disintegrator is selected from
20 chelators or molecules capable of replacing the crosslinking ions.
37. A method according to Claim 36, wherein the disintegrants are selected from: sodium citrate, citric acid EDTA, sodium dodecyl sulphate and other surfactants, phosphate salts, phosphate buffer saline.
38. A method according to claim 34 further comprising adding other polymers
25 internally to the beads to improved permeability , disintegration or release properties and hence dissolution properties of the drug.
39. A method according to claim 34 further comprising adding other polymers externally to the beads to improved permeability , disintegration or release properties and hence dissolution properties of the drug.





Fig. 1A

Fig. 1B

Fig 2





Fig. 3





Fig. 4




Fig 5




Fig 6




fig 7




fig 8